Navamedic ASA: Allocation of shares in the rights issue to primary insiders and their close associates
Navamedic ASA (NAVA) · publisert 2025-10-07 10:55 · vis på NewsWeb
Transaksjoner
| Person | Rolle | Type | Volum | Pris | Dato | ISIN | Handelsplass | Tolket via |
|---|---|---|---|---|---|---|---|---|
| Philip Slätis | Commercial Director RX & International | other | 21,5 | 0 NOK | 2025-10-07 | NO0010205966 | XOFF – Outside a trading venue 21677395/1 2 5 Details of the person discharging managerial responsibilities/person closely associated a) Name Tranbergkollen Invest AS 6 Reason for the notification a) Position/status Close associate to Astrid T. Bratvedt, Chief Scientific Officer in Navamedic ASA b) Initial notification /Amendment Initial notification 7 Details of the issuer, an emission allowances market participant, auction platform, the auctioneer, or the auction monitor a) Business name Navamedic ASA b) LEI code 529900LKVQOR2SRUJU71 8 Details of the transaction(s): Section to be repeated for i) each type of instrument ii) each type pf transaction, iii) each date, and iv) each place where the transaction(s) have been conducted | rules · til gjennomgang |
Vedlegg
- NAVA_Transaction_details.pdf (tekst hentet ut)
Meldingstekst
Oslo, 7 October 2025: Reference is made to the stock exchange announcement
published by Navamedic ASA (the "Company") earlier today regarding the final
result of the rights issue in the Company (the "Rights Issue").
Certain primary insiders, and certain close associates of primary insiders, of
the Company have been allocated shares in the Rights Issue:
Soleglad Invest AS, a company closely associated with Kathrine Elisabeth Gamborg
Andreassen, CEO of the Company, has been allocated 23,260 new shares.
Jostein Davidsen, Chairperson of the Board of Directors of the Company, has been
allocated 17,116 new shares.
Philip Slätis, Commercial Director RX & International of the Company, has been
allocated 3,422 new shares.
Tranbergkollen Invest AS, a company closely associated with Astrid T. Bratvedt,
Chief Scientific Officer of the Company, has been allocated 25,000 new shares.
Jurs AS, a company closely associated with Morten Jurs, board member of the
Company, has been allocated 7,851 new shares.
Please see the attached forms for further details about the transactions.
This information is subject to the disclosure requirements pursuant to article
19 of the EU Market Abuse Regulation and section 5-12 of the Norwegian
Securities Trading Act.